Used in research to modulate hypoxia-inducible factor 2 alpha (HIF-2α) activity, HIF2α-IN-2 is a selective inhibitor that helps study cellular responses to low oxygen conditions. It is applied in cancer research, particularly in tumors where HIF-2α plays a role in growth and survival, such as renal cell carcinoma. By inhibiting HIF-2α signaling, it aids in understanding tumor metabolism, angiogenesis, and potential therapeutic strategies. It is also used to explore diseases involving abnormal HIF pathways, including certain genetic disorders and ischemic conditions.